Predictive value of XPG rs2296147T&#x003E;C polymorphism on clinical outcomes of cancer patients

Yuhan Wang; Yingying Han; Qiang Weng; Zhengrong Yuan

doi:10.18632/oncotarget.11664

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients

Yuhan Wang, Yingying Han, Qiang Weng and Zhengrong Yuan _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:65770-65781. https://doi.org/10.18632/oncotarget.11664

Metrics: PDF 1822 views | HTML 1834 views | ?

Abstract

Yuhan Wang1, Yingying Han1, Qiang Weng1, Zhengrong Yuan1

1College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, People’s Republic of China

Correspondence to:

Zhengrong Yuan, email: [email protected]

Keywords: XPG, rs2296147, cancer, clinical outcomes, meta-analysis

Received: May 24, 2016 Accepted: August 11, 2016 Published: August 29, 2016

ABSTRACT

The Xeroderma pigmentosum complementation group G (XPG) rs2296147T>C polymorphism is suspected to associate with the clinical outcomes of cancer patients. However, the results are inconsistent. This meta-analysis aimed to evaluate the reliable predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients. A total of 11 eligible studies were enrolled in this meta-analysis. Our results indicated that the cancer patients with TT and CT genotypes were significantly associated with better respond rates when compared with the CC genotype (TT versus (vs.) CC: odds ratio (OR) = 2.05, 95% confidence intervals (CIs), 1.32-3.20, P = 0.002; TT+CT vs. CC: OR= 1.57, 95% CI, 1.14-2.17, P = 0.005). The TT genotype and/or T allele might be associated with higher survival time for cancer patients than the CC genotype and/or C allele. The cumulative meta-analyses showed an apparent beneficial objective response of TT genotype on cancer patients. In conclusion, this meta-analysis suggests that the XPG rs2296147T>C polymorphism is associated with the clinical outcomes of cancer patients. The XPG rs2296147T>C polymorphism might be a predictive factor of prognosis in cancers patients and contribute to individual treatment in the future.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11664

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients

Abstract